ACC prevention highlights: New guideline, benefits of statin alternative, prescription fish oil
NEW ORLEANS — The American College of Cardiology Scientific Session provided a number of breakthroughs in CV preventive medicine, including the unveiling of a new primary prevention guideline and vital findings on the benefits of bempedoic acid and icosapent ethyl.
Cardiology Today compiled a list of some of the highlights of the prevention content from the meeting.
New prevention guideline: Collaboration encouraged, aspirin downplayed
NEW ORLEANS — The new prevention guideline from the American College of Cardiology and the American Heart Association emphasizes team-based care and shared decision-making and recommends against use of aspirin for primary prevention in most adults.
Bempedoic acid shows promise for LDL lowering in high-risk patients
NEW ORLEANS — Treatment with bempedoic acid, an investigational oral, once-daily therapy that is designed to work in the liver to inhibit cholesterol biosynthesis, resulted in significant LDL reduction after 12 weeks compared with a placebo in patients at high risk for CV events who were receiving maximally tolerated statin and other lipid-lowering therapy enrolled in the CLEAR Wisdom trial.
Prescription fish oil cuts total ischemic events in new REDUCE-IT analysis
NEW ORLEANS — Icosapent ethyl, a pharmaceutical-grade omega-3 fatty acid, was in the spotlight again at the American College of Cardiology Scientific Session, with new data from the REDUCE-IT trial demonstrating a 30% reduction in total ischemic events, including first and subsequent events, in high-risk patients with elevated triglycerides.
‘Missed opportunity’: Most pregnant women do not undergo lipid screening
NEW ORLEANS — Lipid screening was underutilized in women during pregnancy, with a new study suggesting that up to three-quarters of women were not screened.
High-intensity interval training impacts body composition of patients with metabolic syndrome
NEW ORLEANS — High-intensity interval training led to significant reductions in total body fat, abdominal fat distribution as well as an increase in lean mass compared with moderate-intensity interval continuous training in patients with metabolic syndrome, according to data presented during the American College of Cardiology Scientific Session.
Vaping with e-cigarettes raises odds of CV events, depression
NEW ORLEANS — Adults who reported using electronic cigarettes had increased odds of MI, CAD and depression or emotional problems compared with nonsmokers, according to new data presented at the American College of Cardiology Scientific Session.
Fitness increases survival rates regardless of CV burden in elderly
NEW ORLEANS — Increased fitness in adults aged at least 70 years may lead to better survival rates despite CVD risk factor burden, according to findings presented at the American College of Cardiology Scientific Session.
ODYSSEY Outcomes: Lowering Lp(a), corrected LDL reduce CV events in ACS
NEW ORLEANS — Major adverse CV events were predicted in patients with recent ACS based on their lipoprotein(a) levels at baseline, according to a new analysis of the ODYSSEY Outcomes trial presented at the American College of Cardiology Scientific Session.
Treatment effect of anacetrapib does not vary by ADCY9 genotype
NEW ORLEANS — There was no significant effect of ADCY9 on response to the cholesteryl ester transfer protein inhibitor anacetrapib for major vascular events, according to findings presented at the American College of Cardiology Scientific Session.
Infective endocarditis related to IV drug use increasing hospital admissions, changing treatment paradigm
NEW ORLEANS — Hospital admissions for infective endocarditis related to IV drug use increased by 436% from 2012 to 2017 at Ohio State University Wexner Medical Center, researchers reported at the American College of Cardiology Scientific Session.